Moderate-Severe Plaque Psoriasis (3001)

About Plaque Psoriasis

Psoriasis is a chronic inflammatory skin disease characterized by raised, red oval plaques on the skin with silvery scales. Lesions are typically painful or itchy and can be associated with a high degree of morbidity. Plaques on visible skin have a particular impact on physical, sexual, psychosocial, and even economic status; associated with reduced levels of employment and income. Psoriasis is more than a superficial disease, with 30% of patients having joint involvement, and a high correlation between psoriasis and obesity, diabetes, depression, metabolic syndrome, and cardiovascular risk.

About the Study

We are seeking patients that meet the below criteria to participate in a 56 week study to evaluate the safety and efficacy of TAK-279 and apremilast for the treatment of moderate to severe plaque psoriasis.

Am I Eligible?

• Males and females 18 years or older
• Must have psoriasis involvement of 10% or greater of body surface area (1% is approximately equivalent to the size of your palm)
• Must have diagnosis of chronic plaque psoriasis for at least 6 months prior to enrollment
• No active herpes infection, including herpes zoster, herpes simplex 1 and 2 at initial visit
• Be available for  18 office visits over a 56-week period

Other Information 

No health insurance required, compensation may be provided for your time and participation.

If you are interested in participating in this study, please provide your contact information below and a representative from our research department will be in touch with you.